A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK
-positive, or ROS1-positive non-small cell lung cancer (NSCLC)